Related Experiment Videos

Successful treatment of griseofulvin-resistant tinea capitis in infants

A Lukacs1, H C Korting, A Lindner

  • 1Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Germany.

Mycoses
|November 1, 1994
PubMed

Insights

Itraconazole effectively treated tinea capitis in children caused by Microsporum canis when griseofulvin failed. This antifungal medication offers a superior alternative for difficult-to-treat fungal infections of the scalp.

Area of Science:

  • Dermatology
  • Mycology
  • Pediatric Infectious Diseases

Background:

  • Tinea capitis is a common fungal infection of the scalp, particularly in children.
  • Microsporum canis is a frequent etiological agent of tinea capitis.
  • Griseofulvin is a conventional first-line treatment, but resistance and treatment failures are reported.

Observation:

  • Three siblings (ages 3-8) presented with tinea capitis due to Microsporum canis.
  • Initial treatment with griseofulvin (oral and topical) for 5 months was unsuccessful.
  • The children subsequently received oral itraconazole at 33 mg/day.

Findings:

  • Clinical cure was achieved within 2-5 months of itraconazole therapy.
  • Microbiological cure was confirmed between 5-8 months.
  • Treatment success was dependent on the dosage per kilogram of body weight.

Implications:

  • Itraconazole demonstrates superior efficacy compared to griseofulvin for Microsporum canis-induced tinea capitis.
  • This finding suggests itraconazole as a valuable alternative for refractory cases.
  • Further research into optimal dosing and long-term outcomes is warranted.

Related Concept Videos